Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors.
Topics Covered:
Explore Related Resources:
Dr. Chiesa Fuxench discusses the role of topical ruxolitinib for patients with mild-to-moderate atopic dermatitis, including those who have not responded adequately to topical corticosteroids
Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate atopic dermatitis in nonimmunocompromised patients
Dr. Gooderham discusses using systemic Janus kinase (JAK) inhibitors like upadacitinib in patients with atopic dermatitis. She reviews appropriate indications for patient selection with JAK
David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after
Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch
Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment
Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP
Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for
Dr. Raj Chovatiya presents long-term data on upadacitinib’s ability to maintain skin clearance and itch relief in atopic dermatitis patients over 140 weeks. Topics Covered:
